title: CCR 20th Anniversary Commentary: MAPK/ERK Pathway Inhibition in Melanoma-Kinase Inhibition Redux.
abstract: In the January 15, 2012, issue of Clinical Cancer Research, Kirkwood and colleagues published a study comparing the MEK inhibitor selumetinib with temozolomide in unselected metastatic melanoma. Although selumetinib did not improve survival or response, most responders had BRAF-activating mutations, and selumetinib has since demonstrated efficacy in BRAF-mutant melanoma. This study laid the groundwork for the evaluation of BRAF/MEK inhibitors in BRAF-mutant melanoma.
authors.affiliation: Division of Hematology-Oncology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.
authors.forename: Diwakar
authors.initials: D
authors.lastname: Davar
authors.affiliation: Division of Hematology-Oncology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania. kirkwoodjm@upmc.edu.
authors.forename: John M
authors.initials: JM
authors.lastname: Kirkwood
mesh_terms: D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology*; D001562:Benzimidazoles / Q000008:administration & dosage*; D049109:Cell Proliferation / Q000187:drug effects*; D048049:Extracellular Signal-Regulated MAP Kinases / Q000187:drug effects*; D006801:Humans; D008545:Melanoma / Q000188:drug therapy*
chemical_list: D001562:Benzimidazoles; D048049:Extracellular Signal-Regulated MAP Kinases